Bibliography
- Landis SH , MurrayT, BoldenSet al.: Cancer statistics, 1999.CA Cancer J. Clin.49, 8–31(1999).
- Zanetti R , CrosignaniP, RossoS, Vigane C: Cancer in Italy: incidence data from Cancer Registries. Il Pensiero Scientifico Editore2, 1988–1992(1997).
- Daniele B , SimmondsPD, BestLY, RossPJ, CunninghamD: Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age?Eur. J. Cancer35, 1640–1649(1999).
- Comella P , GambardellaA, FarrisAet al.: A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma. Southern Italy Cooperative Oncology Group trial 0108.Crit. Rev. Oncol. Hematol.53, 133–139(2005).
- Köhne C -H, Cunningham D, Di Costanzo F et al.: Clinical determinants of survival in patiens with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol.13, 308–317(2002).
- Folprecht G , CunninghamD, RossPet al.: Efficacy of 5-fluororacil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.Ann. Oncol.15, 1330–1338(2004).
- Mitry E , Douillard J-Y, Van Cutsem E et al.: Predictive factors for survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann. Oncol.15, 1013–1017(2004).
- Chau I , NormaAR, CunninghamDet al.: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.Br. J. Cancer91, 1453–1458(2004).
- Aparicio T , DesraméJ, LecomteEet al.: Oxaliplatin- or irinotecan-based based chemotherapy for metastatic colorectal cancer in the elderly.Br. J. Cancer89, 1439–1444(2003).
- Comella P , MassiddaB, FilippelliGet al.: Oxaliplatin plus high dose folinic acid and 5-fluoruracil i.v. bolus (OXAFAFU) versus irinotecan plus high dose folinic acid and 5-fluoruracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.Ann. Oncol.16, 878–886(2005).
- Miller AB , HoogstratenB, StaquetM, WinklerV: Reporting results of cancer treatment.Cancer47, 207–221 (1981).
- Kaplan EL , MeierP: Non-parametric estimation from incomplete observations.J. Am. Stat. Assoc.53, 457–481(1958).
- Mantel N : Evaluation of survival data and two new ranks of order statistics arising in its considerations.Cancer Chemother. Rep.50, 163–170(1966).
- Aapro MS , ExtermannM, RepettoL: Evaluation of the elderly with cancer.Ann. Oncol.11(Suppl. 3), 223–229(2000).
- Lichtman SM , SkirvinJA, VemulapalliS: Pharmacology of antineoplastic agents in older cancer patients.Crit. Rev. Oncol. Hematol.46, 101–114(1999).
- Comella P , FarrisA, LorussoVet al.: Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.Br. J. Cancer89, 992–996(2003).
- Goldberg RM : A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer.American Society of Clinical Oncology GI Symposium, San Francisco, CA, USA, 26–28 January (2006).
- Comella P , NataleD, FarrisAet al.: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal cancer. Final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0108.Cancer104, 282–289(2005).
- Cassidy J , TaberneroJ, TwelvesCet al.: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.J. Clin. Oncol.22, 2084–2091(2004).
- Twelves CJ , ButtsCA, CassidyJet al.: Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.Clin. Colorectal Cancer5, 101–107(2005).
- Comella P , MassiddaB, PalmeriSet al.: Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study.Cancer Chemother. Pharmacol.56, 481–486(2005).